Atlas Trials

A Study of the Zanubrutinib Given in Combination With Bendamustine and Rituximab in (Elderly or TP53 Alterations or Chemotherapy Intolerance) Patients With Newly Diagnosed Mantle Cell Lymphoma

Clinical trial NCT06136351 · RECRUITING

Trial details

NCT number
NCT06136351
Sponsor
Ruijin Hospital
Status
RECRUITING
Phase
Phase 2
Study type
INTERVENTIONAL
Lymphoma, Mantle-Cell
Start date
2023-11-15
Primary completion
2027-11-01
Enrollment
23

View on ClinicalTrials.gov

Track trials programmatically

Sponsors, conditions and status changes through the Atlas API.